news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

it house news on october 1st, synchron, an american brain-computer interface company, announced that the non-invasive brain-computer interface it developed has successfully controlled apple vision pro and other devices, and has not experienced serious adverse reactions in clinical trials for one consecutive year.

brain-computer interface is a cutting-edge technology that is attracting much attention in the current consumer market. synchron's minimally invasive brain implant device will begin clinical trials in 2022 and gradually expand from controlling iphone and ipad to controlling apple vision pro.

according to a press release issued by synchron, all six patients who received bci implants had no device-related serious adverse events that could lead to death or permanent disability within one year after surgery. the implanted device caused essentially no problems and was able to stably acquire brain signals related to movement intentions without erratic or inconsistent results.

according to it house, this study called command is the first permanently implanted brain-computer interface trial approved by the fda. unlike other brain implants that require dangerous and invasive surgery, synchron's implant is connected via the jugular vein via a minimally invasive endovascular procedure.

the goal of such implants is to allow patients with severe brain injuries who have been paralyzed by conditions such as stroke to regain some ability to independently perform certain functional activities. patients in the initial trial had severe, chronic bilateral upper limb paralysis that showed no improvement with treatment.

once installed and running properly, the brain-computer interface can interpret signals and convert them into actions such as moving a cursor or clicking, so it can control an iphone, ipad, smart home appliances, or apple vision pro.